Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

Last updated: April 30, 2025
Sponsor: University of Maryland, Baltimore
Overall Status: Active - Recruiting

Phase

2

Condition

Anal Dysplasia

Hiv

Treatment

Human papillomavirus (HPV) vaccine, 9-valent

Clinical Study ID

NCT06624839
HP-00109701
  • Ages 18-70
  • Male
  • Accepts Healthy Volunteers

Study Summary

This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years old or older and 70 years old or younger

  • Able to provide informed consent

  • Denies history of prior HPV vaccination with Gardasil9 (receipt of HPV vaccinationother than Gardasil9 such as the bivalent or the quadrivalent HPV vaccine will beallowed) or unsure of vaccination status and born before 2003

  • Born Male

For Test group: HIV-positive people born male with current or past exposure to androgen blockers or estrogen (BM-EABE)

  • Living with HIV

  • Current or past exposure to androgen blockers or estradiol

For Control group: HIV-negative Control

  • HIV negative

  • Either: Current or past exposure to androgen blockers or estradiol; no current orpast exposure to androgen blockers or estradiol AND had sex with a person with apenis in the last year

Exclusion

Exclusion Criteria:

  • Younger than 18 years old or older than 70 years old.

  • Self-reported or documented history of nine-valent HPV vaccine or unsure ofvaccination status and born after 2003.

  • Born female

  • History of hypersensitivity, including severe reactions to yeast or other componentof the vaccine.

  • Any condition requiring systemic chemotherapy or immunomodulant affecting antibodyresponses (i.e., rituximab, ibrutinib etc.), intravenous or subcutaneousimmunoglobulin supplementation, radiation therapy, or immunomodulatory treatmentwithin the previous 6 months (presence of precancerous lesions is not exclusionary).

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Human papillomavirus (HPV) vaccine, 9-valent
Phase: 2
Study Start date:
March 15, 2025
Estimated Completion Date:
January 31, 2028

Study Description

This will be a phase 2, open-label study to assess the humoral and cellular immune response to the FDA-approved 9-valent HPV recombinant vaccine in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). At baseline, BM-EABE with HIV, HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) will provide blood samples and anal swabs for evaluation of HPV immunity, anal HPV and anal dysplasia. All participants will undergo a 3-dose vaccine series of the Gardasil vaccine (at Day 0, Month 2 and Month 6). Participants will then return one month after completion of third vaccine (Month 7) to provide repeat blood samples and anal swabs. Samples will be compared pre and post vaccination and in-between participants based on HIV and exposure to androgen blockers or estrogen (EABE).

Any participant with human papillomavirus 16 (HPV16) and/or anal dysplasia on anal cytology at any point will be referred to high-resolution anoscopy (HRA) for clinical management. Anal biopsies will be procured from different pathology laboratories - after clinical evaluation has been complete - for research analysis, including confocal microscopy. Those who had anal dysplasia at study entry will undergo repeat HRA, as clinically indicated, and will have an optional study visit following their repeat HRA to provide blood draw and anal swabs.

Connect with a study center

  • RIIS Clinic at HIPS

    Washington, District of Columbia 20002
    United States

    Site Not Available

  • RIIS Clinic at Baltimore Safe Haven

    Baltimore, Maryland 21201
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.